Xeris Biopharma (XERS) Scheduled to Post Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) will issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Xeris Biopharma has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Xeris Biopharma had a negative net margin of 37.98% and a negative return on equity of 610.76%. The company had revenue of $44.39 million during the quarter, compared to the consensus estimate of $45.50 million. During the same period in the previous year, the company earned ($0.10) earnings per share. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Stock Performance

Shares of XERS opened at $1.88 on Wednesday. The company has a current ratio of 1.64, a quick ratio of 1.23 and a debt-to-equity ratio of 49.27. Xeris Biopharma has a 52 week low of $1.46 and a 52 week high of $3.26. The firm’s 50-day simple moving average is $2.12 and its 200 day simple moving average is $2.21.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on XERS. HC Wainwright increased their target price on Xeris Biopharma from $5.50 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, March 7th. Oppenheimer started coverage on Xeris Biopharma in a research report on Thursday, March 28th. They set an “outperform” rating and a $5.00 price objective on the stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.